Pfizer, the Pharmaceutical Express, has invested $200 million in Keystone Pharmaceuticals.

September 30, 2020 / Medical Information List: 100% of such clinics are spot-checked; Ironwood suspends research and development of GERD drugs and lays off 100 people; Myovant publishes clinical failure data for Stage 3 of Relugolix prostate cancer; regeneratives: preliminary clinical results of new coronary and antibody therapy ... Daily fresh medicine news, speed reading society and you pay attention to! Policy Brief A shortage of drugs hanging network, Jiangsu Province Announcement Resources Trading Center issued a notice on the publication of shortage of drugs directly online procurement of products.
The shortage of drugs announced by the Jiangsu Provincial Drug Administration is: injection of urine kinase, injection of hydrochloric acid flatamycin, methionate nismin injection, injection of hydrochloric acid bolemycin;
will be implemented on 1 October 2020.
(Jiangsu Province Announcement Resource Trading Center) Health Supervision Institute issued 100% of such clinics were spot-checked 28, according to the Tianjin Municipal Health Supervision Institute, in accordance with the "City Health and Health Commission on the field of health and health "double random one open" supervision of spot checks" requirements, Tianjin Municipal Supervision Institute organized the first city-wide Chinese medicine health supervision "double random, one open" supervision spot checks.
the target of this spot check for the city-wide development of Chinese medicine services for-profit medical institutions, the proportion of spot checks is 35%.
, the proportion of spot checks on Chinese medicine filing clinics was 100%.
announced that it was in the process of restructuring its organizational structure, including cutting up to 100 full-time employees and suspending research and development of its refroutable gastroesoesic reflow drug IW-3718, just days after the company suspended the development of GERD drugs and laid off 100 workers.
comes after Ironwood reviewed non-blind data from phase III clinical trial IW-3718-302 of the company's GERD drug, which failed to reduce heartburn in patients.
(Xinhua) -- Pfizer's $200 million investment in Keystone Pharmaceuticals resulted in a PD-L1 antibody clinical development and commercial partnership between Cornerstone Pharmaceuticals and Pfizer subsidiary Pfizer Investment and Pfizer Hong Kong announced a strategic partnership that includes Pfizer Hong Kong's investment in Keystone Pharmaceuticals. With a $200 million equity investment, Keystone Pharmaceuticals and Pfizer invested in the development and commercialization of Shugli Monoanti (PD-L1 Antibodies) in Chinese mainland, as well as Cornerstone Pharmaceuticals and Pfizer's investment in bringing more tumor products to the Greater China framework of cooperation.
(Immediate Drug News) Regency Bio intends to introduce the IL-2 series of products Regency Bio announced that it intends to sign a license agreement with Anwita, Anwita will grant Regency Bio in the licensing area alone use of the Anti-HSA-IL-2N alpha series, etc.
, Regency will make a $2 million down payment to Anwita and a milestone payment of up to $86 million to Anwita based on research and development and commercialization progress.
(Junshi Bio-Announcement) Yuyuan Pharmaceuticals and Jingyun Pharmaceuticals reached a strategic cooperation on the 28th, Yuyuan Pharmaceuticals announced that it signed a Strategic Cooperation Agreement with Jingyun Pharmaceuticals, establishing a strategic partnership between the two sides.
announced that, based on the advantages of the two companies, the two sides decided to use innovative crystalline technology and preparation technology to develop the Chinese and U.S. market first generic drugs and high-end generic drugs, and will actively work on the higher patent and technology threshold of the first generic drugs and high-end generics development and industrialization.
aligos announced the filing of an IPO application, Aligos announced that it had filed an IPO application to land on NASDAQ.
$100 million is planned after Aligos completed a $100 million round of A financing in 2018 and a $125 million round of B financing in January.
(Xinhua) -- Myovant released data on the clinical failure of Relugolix Prostate Cancer Phase 3 on the 29th, Myovant published a secondary endpoint results of phase 3 clinical study HERO evaluating patients with advanced prostate cancer who received relugolix treatment.
the study showed that relugolix did not have a statistical advantage in treating the despotic resistance survival rate of patients with metastatic prostate cancer for 48 weeks compared to the gontheproof hormone drug acetate.
(Sina Pharmaceutical News) Regenerative Meta: New Coronary neutral antibody therapy preliminary clinical results Regeneration Meta has published its research new coronavirus neutral and antibody cocktail therapy REGEN-COV2 in seamless phase 1/2/3 clinical trials obtained by the preliminary descriptive data.
data show that REN-COV2 reduces viral load and reduces the time required for symptom relief when treating non-hospitalized COVID-19 patients.
reGEN-COV2 also showed a positive trend in reducing patient visits to hospitals.
( Pharmaceuticals ) " first-in-class" therapy has been approved by the FDA for priority review of the treatment of the deadly MoCD BridgeBio and its subsidiary Origin announced that the FDA has accepted and granted priority review qualifications for fosdenopterin.
Fosdenopterin is a "first-in-class" cPMP hydrobromohydrate hydrate hydrate.
as a cyclophosphate substrate replacement therapy for the treatment of patients with type A cofactor deficiency (MoCD).
(Pharmaceutical Mingkangde) Takeda Pharmaceutical TAK-788 capsules to be included in the breakthrough therapy CDE to be included in the breakthrough therapy column update on the 29th, Takeda Pharmaceuticals TAK-788 capsules to be included.
TAK 788 is a small molecular inhibitor with oral activity targeting EGFR and HER2 mutations and is selective for wild type EGFR.
is the first new drug to have a breakthrough effect on EGFR 20 exon insertion mutations.
(CDE) Jansen double anti-JNJ-61186372 to be included in the breakthrough therapy 29, CDE to be included in the breakthrough therapy column update, Jansen double anti-JNJ-61186372 to be included.
JNJ-61186372 is a two-specific antibody developed by Jansen that targets EGFR and cMET, and the adaptation to this proposed breakthrough therapy is to treat patients with platinum-containing dual-drug chemotherapy during or after progression, or metastasis or surgically unseistable NSCLC patients with EGFR20 exon insertion mutations that are not resistant to platinum chemotherapy.
(CDE) Huahai Pharmaceutical HB002.1M was approved 3 clinical 28, Huahai Pharmaceuticals issued a notice that subsidiary Huabo Bio's recombinant human endotrine growth factor subject-antibody fusion protein eye injection (HB002.1M) project 3 new adaptations, approved by the State Drug Administration clinical.
To date, HB002.1M has four adaptation disorders (wet age-related macular degeneration, retinal branch vein blockage secondary macular edema, retinal central venous blockage secondary macular edema and diabetic macular edema) approved for clinical use.
the first adaptive wet age-related macular degeneration trial with HB002.1M has progressed to Phase II clinical.
(Huahai Pharmaceutical Announcement) PCCW Biopropulphol / Long Chain Fat Milk Injection is expected to be the first to be evaluated recently, Jiangsu PCCW Bio according to the imitation of 4 categories of reported propofol medium / long chain fat milk injection (receiving number CYHS1900274) registration status changed to "in approval", is expected to be approved and the first review.
(Mi net) Baiji Shenzhou Ditoxi monoanti and Zebtini to be included in the priority review of CDE 29 publicity, Baiji Shenzhou 2 new drugs to be included in the priority review.
one of these is a ditoxidant injection, which is being developed to treat a variety of neuroblastomas.
according to public information, this is the monoclonal antibody QARZIBA, introduced from EUSA Pharma in Baiji Shenzhou earlier this year, which can bind to GD2.iii, a specific target for overexposed neuroblastoma cells.
the other is the BTK inhibitor Zebutinib capsule, which is included in the priority review of the adaptation: suitable for the treatment of adult patients with fahrenheit globulinemia.
(CDE) Dupree monoantigen was approved in China in March after submitting a second listing application Sanofi Du Puliu single anti-injection application in China submitted a second listing application was accepted by CDE, just about three months after the drug was first approved in China.
was approved by the NMPA in June this year for the treatment of adults with moderate to severe endexual dermatitis with poor control of prescription drugs for external use or not recommended for use with prescription drugs for use in adolescents and adults 12 years of age and older.
(CPhI Pharmaceuticals Online)